|
KMID : 1145520220080020103
|
|
Journal of Radiopharmaceuticals and Molecular Probes
2022 Volume.8 No. 2 p.103 ~ p.111
|
|
|
Medical Imaging and Nuclear Molecular Imaging Probes for Pulmonary Fibrosis Diagnosis
|
|
Ahn Hee-Su
Lee Yong-Jin
|
|
|
Abstract
|
|
|
|
Idiopathic pulmonary fibrosis (IPF) is a progressive disease caused by some risk factors, including smoking, viral infection, toxic substances, and radiation, that decline lung function of fresh oxygen and blood delivery throughout the body. Patients with pulmonary fibrosis have suffered from breathing and cough and the average survival rate is only 3 years after diagnosis. Therefore, it is significant to diagnose IPF and start treatment in enough time. Usually, lung biopsy is available to diagnose localized pulmonary fibrotic sites directly. However, it is insufficient to visualize whole lung tissue, and also it has a risk of infection for patients. In the clinic, medical imaging systems can diagnose pulmonary fibrosis non-invasively without infection. In this review, we introduce current medical imaging systems used to diagnose pulmonary fibrosis, including CT, MRI, and nuclear medicine. Further, we introduce several molecular imaging probes targeting specific biomarkers which are expressed in pulmonary fibrosis. Through this paper, it is expected that it would be helpful to understand the latest knowledge and research trends on pulmonary fibrosis diagnostic imaging.
|
|
|
KEYWORD
|
|
|
Nuclear medicine imaging, Pulmonary fibrosis, Radiopharmaceuticals
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|